Year: 2017
Type: review
Abstract: Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in developed countries because of the obesity epidemic. The disease increases liver-related morbidity and mortality, and often increases the risk for other comorbidities, such as type 2 diabetes and cardiovascular disease. Insulin resistance related to metabolic syndrome is the main pathogenic trigger that, in association with adverse genetic, humoral, hormonal and lifestyle factors, precipitates development of NAFLD. Biochemical markers and radiological imaging, along with liver biopsy in selected cases, help in diagnosis and prognostication. Intense lifestyle changes aiming at weight loss are the main therapeutic intervention to manage cases. Insulin sensitizers, antioxidants, lipid lowering agents, incretin-based drugs, weight loss medications, bariatric surgery and liver transplantation may be necessary for management in some cases along with lifestyle measures. This review summarizes the latest evidence on the epidemiology, natural history, pathogenesis, diagnosis and management of NAFLD.
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: non-alcoholic fatty liver disease, obesity, insulin resistance, metabolic syndrome, type 2 diabetes, cardiovascular disease, NAFLD pathogenesis, NAFLD diagnosis, NAFLD management, lifestyle intervention, weight loss, insulin sensitizers, antioxidants, lipid-lowering drugs, incretin-based therapy, bariatric surgery, liver transplantation, natural history (disease)
Open Access status: diamond
OpenAlex ID: W2736924678
